Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma

Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway are expected to be a novel therapy for combating future increases in numbers of malignant pleural mesothelioma (MPM) patients. However, the PD-L1 expression, which is a predictor of the response to ICIs, is unclear in MPM. We studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Takuya, Okuda, Katsuhiro, Murase, Takayuki, Moriyama, Satoru, Haneda, Hiroshi, Kawano, Osamu, Yokota, Keisuke, Sakane, Tadashi, Oda, Risa, Inagaki, Hiroshi, Nakanishi, Ryoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945532/
https://www.ncbi.nlm.nih.gov/pubmed/29755688
http://dx.doi.org/10.18632/oncotarget.25100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945532/
https://www.ncbi.nlm.nih.gov/pubmed/29755688
http://dx.doi.org/10.18632/oncotarget.25100

Ejemplares similares